Daytime intragastric acid control: Post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors

Philip Katz*, Peter J. Kahrilas, David A. Johnson, Tore Lind, Kerstin Rohss, Barry Traxler, Vincent Hugo, John Dent

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

In mild gastroesophageal reflux disease, which accounts for the great majority of cases, the major burden of reflux occurs during daytime hours, after food intake. The aim of these analyses was to evaluate intragastric pH control during the typical 14-hour daytime awake period by proton-pump inhibitors (PPIs) given at over-the-counter (OTC) dosages. Methods: In one double-blind and three open-label, randomized, crossover studies, intragastric pH was monitored for 24 hours on day 5 of treatment. The 24-hour data have been reported previously. Post hoc analyses reassessed these studies for the 14-hour daytime period, comparing esomeprazole 20 mg with currently available OTC PPIs omeprazole, pantoprazole (not available in the US) and lansoprazole. Results: Subjects maintained intragastric pH >4 for a significantly greater mean percentage of the 14-hour daytime period with esomeprazole 20 mg compared with any of the PPI comparators at OTC dosages. Geometric mean ratios (95% confidence intervals) for esomeprazole 20 mg versus the comparators were: 1.45 (1.14–1.85; p = 0.003) versus omeprazole 20 mg; 2.50 (2.01–3.11; p < 0.0001) versus pantoprazole 20 mg; and 1.69 (1.46–1.97; p < 0.0001) and 1.89 (1.05–3.37; p = 0.03) versus lansoprazole 15 mg. A greater proportion of subjects had better pH control with esomeprazole than with the other PPIs (range: 69–97%). Across the 14-hour daytime period, esomeprazole 20 mg once daily given 30 minutes before breakfast for 5 days provided acid control for a significantly greater average proportion of time versus the PPI comparators omeprazole, pantoprazole and lansoprazole at currently available OTC dosages.

Original languageEnglish (US)
Pages (from-to)322-330
Number of pages9
JournalTherapeutic Advances in Gastroenterology
Volume8
Issue number6
DOIs
StatePublished - Nov 2015

Funding

All studies were funded by AstraZeneca, which entered into an agreement with Pfizer for the over-the-counter (OTC) rights for NEXIUM (esomeprazole magnesium). Medical writing support was provided by Diane Sloan, PharmD, of Peloton Advantage, LLC, and was funded by Pfizer. ®

Keywords

  • esomeprazole
  • gastric acid inhibitors
  • gastroesophageal reflux
  • intragastric pH
  • proton pump inhibitors

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Daytime intragastric acid control: Post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors'. Together they form a unique fingerprint.

Cite this